Ab­b­Vie re­treats as Gala­pa­gos of­fers mixed PhII CF da­ta, leav­ing a ma­jor al­liance in per­il — Ver­tex shares surge

Gala­pa­gos $GLPG out­lined some dis­tinct­ly mixed re­sults from its Phase II study of its C2 cor­rec­tor GLPG2737 for cys­tic fi­bro­sis Thurs­day af­ter­noon, man­ag­ing to boost …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER